Viewing nowDafos 10 mg (Dapagliflozin Propanediol Monohydrate)
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Bainex Co., Ltd.

MFDS item code 202300256 · Approved 2023.01.16 · Insurance code 643105700
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. It can be used alone or in combination with other antidiabetic agents. Especially in patients whose blood sugar is not adequately controlled and who have cardiovascular diseases or risk factors, this drug may affect the occurrence of cardiovascular events, necessitating professional caution. Therefore, it is used to improve blood sugar safely according to the patient's condition.
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10 mg once daily for monotherapy and add-on combination therapy with other antihyperglycemic agents, including insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received antidiabetic drug therapy, the recommended initial dose of this medicine when administered in combination with metformin is 5 mg once daily or 10 mg once daily. Special populations Renal impairment - eGFR below 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10 mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet must be swallowed whole.
Children under 18 years of age: The efficacy and safety of dapagliflozin have not been established. No relevant data are available.
This medication should not be used in specific patients. For example, patients allergic to the active ingredient or excipients, patients with type 1 diabetes, patients with diabetic ketoacidosis, patients with lactose intolerance or related genetic disorders, and patients undergoing dialysis should not receive this medication. This drug should be used cautiously in patients with reduced fluid volume or renal impairment. This medication can lower blood pressure or affect renal function, so fluid status and renal function must be evaluated before administration, and hypotensive symptoms and changes in renal function should be carefully monitored during treatment. In clinical trials, patients taking this medication reported side effects such as genital infections, urinary tract infections, hypoglycemia, fluid volume depletion, and diabetic ketoacidosis. Particularly, genital infections may occur more frequently in females and in patients with a history of past infections. The blood sugar control effect of this medication varies depending on renal function, and in patients with moderate or severe renal impairment, the effect on blood sugar control may be reduced. Additionally, upon initial administration, serum creatinine levels may temporarily increase, necessitating attention. During this medication period, there is a risk of diabetic ketoacidosis; if symptoms such as dehydration, vomiting, abdominal pain, and respiratory distress occur, the patient should immediately consult medical personnel. Moreover, this medication may increase the risk of serious urinary tract infections such as urinary tract infections and pyelonephritis, thus prompt treatment is necessary if infection symptoms are present. Elderly patients or those taking diuretics should be especially cautious due to a higher risk of fluid volume depletion and hypotension. When co-administering this medication with hypoglycemic agents such as insulin or sulfonylureas, the risk of hypoglycemia may increase, therefore attention to hypoglycemic symptoms is recommended, and dose adjustment of concomitant medications may be necessary. It is recommended that women who are pregnant or breastfeeding do not use this medication, and if pregnancy is confirmed, administration should be immediately discontinued. There is no specific antidote for overdose; appropriate symptomatic treatment should be conducted based on the patient's condition. This medication does not significantly affect the ability to drive or operate machinery, but caution is needed due to the risk of hypoglycemia.
Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decrease in fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, increased hematocrit, initial treatment decrease in renal creatinine clearance, dyslipidemia, initial treatment increase in blood creatinine, elevated blood urea, weight loss, acute pyelonephritis, chest pain, rash, angioedema, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina, myocardial infarction, choledocholithiasis, cholangitis, alcoholic cirrhosis, depression, suicide attempt, gastric adenocarcinoma, anaphylactic reaction, sensory disturbances, cerebral infarction, nerve compression, urosepsis, pyelonephritis, ligament sprain, urticaria, cold sweat, flank pain, fibromyalgia, limb discomfort, muscle cramps, musculoskeletal discomfort, osteopenia, contusion, road traffic accident, drug overdose, ankle fracture, hand fracture, iliac bone fracture, meniscus injury, thoracic vertebra fracture, tibial fracture, dental injury, dry eye, ocular pain, retinal disorders, visual impairment, blepharitis, cataract, conjunctival edema, allergic conjunctivitis, conjunctivitis, diplopia, eyelid edema, hypertonia, visual impairment, vitreous floaters, oral-pharyngeal pain, allergic rhinitis, asthma, voice disorders, epistaxis, sleep apnea syndrome, wheezing, arteriosclerosis, flushing, peripheral coldness, varicose veins, vascular headache, orthostatic hypotension, atrial fibrillation, diastolic dysfunction, anxiety disorder, enuresis, auditory hallucinations, sleep disorders, insomnia, fatty liver, gallbladder polyp, tinnitus, anal genital warts, gastric adenoma, neurofibroma, unspecified pituitary neoplasm, male hypogonadism, thyroid cyst, thyroid nodule, food allergy, erythrocytosis, dyspepsia, nausea, diarrhea, vomiting, urinary retention, urinary abnormalities, increased alanine aminotransferase, increased aspartate aminotransferase, weight gain, decreased appetite, hyperphagia, increased appetite, headache, sensory hyposthesia, nasopharyngitis, upper respiratory infection, chest discomfort, peripheral edema, generalized edema, hunger, vaginal discharge, menstrual disorder, itching, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, ligament sprain, diabetic retinopathy, cough, dyspnea, palpitations
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to avoid exposure to air or moisture, and it is safe to store at room temperature between 1 to 30 degrees Celsius.
Yellow, convex, diamond-shaped film-coated tablet
28 tablets/bottle, 30 tablets/bottle, 30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowDapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Bainex Co., Ltd.
Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.
Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Sung IS Co., Ltd.
Dapagliflozin Propanediol Hydrate
Prescription medication
Optus Pharmaceutical Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Aprogen Biologics Co., Ltd.

Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.